New Parkinson's shot enters first human safety tests
NCT ID NCT07422675
Summary
This is a first-in-human study to check the safety and how the body processes a new single-injection drug called SER-252. It is for people with Parkinson's disease who experience daily 'off' periods where their medication wears off and symptoms return. The study will give increasing doses to small groups of participants to find a safe level.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE (DISORDER) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CMAX
RECRUITINGAdelaide, South Australia, 5000, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Monash
RECRUITINGMelbourne, Victoria, 3170, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Quest Research Institute
NOT_YET_RECRUITINGLake Mary, Florida, 32746, United States
-
Velocity Clinical Research
NOT_YET_RECRUITINGDurham, North Carolina, 27701, United States
Conditions
Explore the condition pages connected to this study.